Complete Pathologic Response When Adding Pembrolizumab to Neoadjuvant Chemotherapy in Stage IIIA Non-Small-Cell Lung Cancer

被引：5
|
作者：
Hill, Addie [1 ]
Gong, Jun [1 ]
Wilczynski, Sharon [1 ]
Mirza, Rizvan [1 ]
Erhunmwunsee, Loretta [1 ]
Salgia, Ravi [1 ]
机构：
[1] City Hope Canc Ctr, Duarte, CA USA
来源：
JOURNAL OF ONCOLOGY PRACTICE | 2018年 / 14卷 / 09期
关键词：
D O I：
10.1200/JOP.18.00127
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：569 / +
页数：5
相关论文
共 50 条
  • [41] Neoadjuvant Chemotherapy Plus Immunotherapy in Early-Stage Resectable Non-Small-Cell Lung Cancer
    Passaro, Antonio
    Attili, Ilaria
    de Marinis, Filippo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (25) : 2871 - 2022
  • [42] Pembrolizumab in Non-Small-Cell Lung Cancer REPLY
    Reck, Martin
    Brahmer, Julie R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (10): : 997 - 997
  • [43] Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
    Garon, Edward B.
    Rizvi, Naiyer A.
    Hui, Rina
    Leighl, Natasha
    Balmanoukian, Ani S.
    Eder, Joseph Paul
    Patnaik, Amita
    Aggarwal, Charu
    Gubens, Matthew
    Horn, Leora
    Carcereny, Enric
    Ahn, Myung-Ju
    Felip, Enriqueta
    Lee, Jong-Seok
    Hellmann, Matthew D.
    Hamid, Omid
    Goldman, Jonathan W.
    Soria, Jean-Charles
    Dolled-Filhart, Marisa
    Rutledge, Ruth Z.
    Zhang, Jin
    Lunceford, Jared K.
    Rangwala, Reshma
    Lubiniecki, Gregory M.
    Roach, Charlotte
    Emancipator, Kenneth
    Gandhi, Leena
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (21): : 2018 - 2028
  • [44] Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
    Vozy, A.
    Zalcman, G.
    ONCOLOGIE, 2015, 17 (09) : 407 - 408
  • [45] Pathologic Response and Survival after Neoadjuvant Chemotherapy with Bevacizumab Followed by Surgery for Clinical Stage II/IIIA Nonsquamous Non-Small-Cell Lung Cancer: Results from a Phase II Feasibility Study (NAVAL)
    Tsutani, Yasuhiro
    Miyata, Yoshihiro
    Suzuki, Kenji
    Tanaka, Fumihiro
    Ito, Hiroyuki
    Yamashita, Yoshinori
    Okada, Morihito
    CANCERS, 2024, 16 (13)
  • [46] Outcomes of surgical resection after neoadjuvant chemoimmunotherapy in locally advanced stage IIIA non-small-cell lung cancer
    Romero Roman, Alejandra
    Campo-Canaveral de la Cruz, Jose Luis
    Macia, Ivan
    Escobar Campuzano, Ignacio
    Figueroa Almanzar, Santiago
    Delgado Roel, Maria
    Galvez Munoz, Carlos
    Garcia Fontan, Eva M.
    Muguruza Trueba, Ignacio
    Romero Vielva, Laura
    Cano Garcia, Jose Ramon
    Martinez Tellez, Elisabeth
    Partida Gonzalez, Concepcion
    Jimenez Lopez, Marcelo Fernando
    Jimenez Maestre, Unai
    Mongil Poce, Roberto
    Sanchez Lorente, David
    Alvarez Kindelan, Antonio
    Provencio Pulla, Mariano
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2021, 60 (01) : 81 - 88
  • [47] Neoadjuvant chemoradiotherapy followed by surgery for stage IIIa and IIIb non-small-cell lung cancer (NSCLC): is it still justified?
    Mirimanoff, Rene-Olivier
    CHINESE CLINICAL ONCOLOGY, 2015, 4 (04)
  • [48] Distinct patterns of angiogenic factor expression as a predictive factor of response to chemotherapy in stage IIIA non-small-cell lung cancer patients
    Koufos, Nikolaos
    Syrios, John
    Michailidou, Despina
    Xynos, Ioannis D.
    Lazaris, Andreas
    Kavantzas, Nicolaos
    Tomos, Periclis
    Kakaris, Stamatis
    Kosmas, Christos
    Tsavaris, Nikolas
    MOLECULAR AND CLINICAL ONCOLOGY, 2016, 5 (04) : 440 - 446
  • [49] Induction chemotherapy in early stage non-small-cell lung cancer
    Katherine M. W. Pisters
    Current Oncology Reports, 2003, 5 (4) : 307 - 308
  • [50] Neoadjuvant atezolizumab plus chemotherapy in resectable non-small-cell lung cancer
    Rosell, Rafael
    Ito, Masaoki
    LANCET ONCOLOGY, 2020, 21 (06): : 736 - 738
12345